138 related articles for article (PubMed ID: 36832093)
1. Relevance of Volumetric Parameters Applied to [
Urso L; Castello A; Treglia G; Panareo S; Nieri A; Rambaldi I; Caracciolo M; Ortolan N; Uccelli L; Cittanti C; Castellani M; Bartolomei M
Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832093
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
[TBL] [Abstract][Full Text] [Related]
3. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849
[No Abstract] [Full Text] [Related]
5. Inflammation-Based Index and
Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
[TBL] [Abstract][Full Text] [Related]
6. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
7. [
Laudicella R; Comelli A; Liberini V; Vento A; Stefano A; Spataro A; Crocè L; Baldari S; Bambaci M; Deandreis D; Arico' D; Ippolito M; Gaeta M; Alongi P; Minutoli F; Burger IA; Baldari S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205733
[TBL] [Abstract][Full Text] [Related]
8.
Liberini V; Rampado O; Gallio E; De Santi B; Ceci F; Dionisi B; Thuillier P; Ciuffreda L; Piovesan A; Fioroni F; Versari A; Molinari F; Deandreis D
Front Med (Lausanne); 2020; 7():601853. PubMed ID: 33575262
[No Abstract] [Full Text] [Related]
9. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
12. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
15. Glucose Metabolism Modification Induced by Radioligand Therapy with [
Urso L; Panareo S; Castello A; Ambrosio MR; Zatelli MC; Caracciolo M; Tonini E; Valpiani G; Boschi A; Uccelli L; Cittanti C; Bartolomei M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297443
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
18. Quantitative
Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
[TBL] [Abstract][Full Text] [Related]
19. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
20. Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by
Jahn U; Ilan E; Velikyan I; Fröss-Baron K; Lubberink M; Sundin A
EJNMMI Res; 2021 Nov; 11(1):118. PubMed ID: 34822040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
